Meet our Team

Rob is a co-founder and has served as President and CEO of Kenjockety since its inception in 2017. Prior to founding Kenjockety, Rob helped pioneer the development of ADC therapeutics targeting cancer stem cells at Stemcentrx Inc., a startup company acquired by Abbvie Inc. Over 22 years at Genentech, Inc, Rob held various leadership roles, including VP of Process Sciences, leading manufacturing operations and leading the team that pioneered the cell culture systems used for production and approval of the first human biologics manufactured using Chinese Hamster Ovary (CHO) cells. Rob and his teams were responsible for the development of processes for clinical testing and regulatory approval of: ACTIVASE®, PULMOZYME®, LUCENTIS®, PROTROPIN®, ACTILYSE®, and the antibodies XOLAIR®, HERCEPTIN®, RITUXAN® and others. Rob and colleagues at Genentech pioneered the use of common light chain methods for bispecific antibody generation. Rob started his career at Burroughs Wellcome as a scientist developing viral vaccines, and cell culture systems for pilot and commercial applications. Rob has presented at numerous international conferences, has published several papers, holds several patents, and was the recipient of the 2006 Merck Cell Culture Engineering award. Rob holds a B.Sc in Biochemistry & Physiology and an M.S in Industrial Microbiology, from the University of London and a Ph.D. in Mammalian Cell Culture and Virology from the University of London (supervised by Professor John Pirt).

Philippa is the co-founder of Kenjockety and has served as CFO since its inception in 2017. Philippa has worked in the biopharmaceutical industry for over 30 years in a variety of leadership roles encompassing business strategy, supply chain strategy, contract manufacturing management, and plant management at Genentech Inc./Roche AG, SmithKline Beecham Plc., and Eli Lilly and Co. Philippa has worked extensively in drug substance and drug product arenas for commercial and development products, encompassing small molecules, biologics and antibody drug conjugates. At Genentech, Philippa was VP Global Supply Chain and as VP Manufacturing Collaborations was responsible for Roche’s global outsourced manufacturing. Philippa is an experienced leader of post-merger/acquisition integrations and the implementation of operational excellence programs. Philippa earned her BSc. degree in Biochemistry from University of Warwick and MBA from Warwick Business School in the UK.

Brian is an independent consultant and has served as our Interim Head of Business Development since May 2020 and as a Strategic Advisor since November 2018. Brian is the Principal and Founder of Boston BioConsulting, LLC, a biopharmaceutical strategic advisory consulting firm established in September 2010. Brian has over 25 years of experience in the biopharmaceutical industry the includes licensing, collaborations, acquisitions, financings, and multiple product launches in numerous commercial leadership roles. Prior to joining us, Brian served as Chief Commercial Officer and Head of Business Development at NewLink Genetics from January 2013 to July 2018. Additionally, he served in various leadership and management roles at Celgene, Gloucester Pharmaceuticals, Millennium and Aventis. Brian has a Marketing degree from the Pennsylvania State University.

Raffaella has served as Kenjockety’s Head of Antibody Engineering since November 2017. She has almost 20 years of experience in the biopharmaceutical industry as Protein Engineer and Molecular Biologist with extensive experience in protein and antibody engineering and production. In particular, she contributed to the design, optimization, and validation of several bispecific scaffolds for therapeutic antibodies. Prior to joining Kenjockety, Raffaella served as Senior Scientist with Cytomx Therapeutics Inc. where she directed a team in Protein Engineering Group responsible for initiating and executing therapeutic antibody discovery projects. Additionally, she served as Senior Scientist at Compugen Inc. directing the Protein Sciences Group to establish antibody expression and purification systems and to generate cell lines of Compugen proprietary antigens. Previously, she was scientist/ senior scientist at Takeda California and Sea Lane Biotechnologies. Raffaella earned her BS Degree in Inorganic and Physical Chemistry and her PhD in Industrial Biotechnology from the University of Naples “Federico II”, Italy. She was a Post Graduate Fellow and a Doctoral Research Fellow at the Italian National Research Council.

Paul has served as Kenjockety’s Head of Antibody Development since July 2019. Paul is an immunologist with more than 25 years of biopharmaceutical industry experience applying principles of immune response and its regulation to the discovery and development of immune modulating antibodies, including Fc-modified antibodies and antibody drug conjugates. He has served as team lead on a number of autoimmune, oncology and immuno-oncology programs from early target discovery through pre-clinical development including target validation, assay development, antibody lead selection, and in vivo efficacy, PK, PD and safety studies. Prior to joining Kenjockety Paul served as Director of Immunology with RubrYc Therapeutics Inc., and prior to that as a Senior Scientist at Bristol Myers Squibb. In addition, Paul has held positions of increasing responsibility at several biotech start-up companies including LeukoSite Inc. and Tolerx Inc. Paul received a Ph.D. in Microbiology from The University of Texas, Austin, and post-doctoral training at Harvard University as an Arthritis Foundation Fellow and Investigator.

Steve is an independent, international management consultant, having spent the last decade working in diverse locations such as India, Australia, China, Europe, Saudi Arabia, and the US. Steve has over 35 years of experience in global supply chain, manufacturing, service and support, and product development across a wide range of companies – from Fortune 100 companies to early stage startups – and in a diverse range of industries – telecom, technology, industrial, aerospace, and life sciences. Steve assists Kenjockety Biotechnology in the areas of IT, business strategy, and program management. Steve worked at PRTM Management Consultants for 22 years and was a partner for 15 years. Steve established the US West Coast Life Sciences practice and opened PRTM’s first office in a developing market, India. He began his operations-oriented career as a Manufacturing Engineer and Manufacturing Manager for Abbott Laboratories. Steve is a Distinguished Graduate of the United States Air Force Academy with a BS Degree in Engineering Science and Mechanics (ESM). He also has an MS Degree in ESM from Georgia Institute of Technology and an MBA from Golden Gate University.

Pam has served as an Advisor to Kenjockety since April 2019. She is Founder and Principal of PMK BioResearch offering advisory and strategic consulting for the biotechnology industry and venture firms. Pam is a member of the Board of Directors of Argenx, Patrys, Spring Bank Pharmaceuticals and I-Mab Biopharma as well as a member of several Scientific Advisory Boards. She is Chief Medical Officer (CMO) for Olema Oncology and was previously CMO for multiple successful biotech companies. From 2001-2008, Pam held increasing positions of responsibility at Genentech lastly as Vice President, Development, where she led the development for a portfolio of drugs including HERCEPTIN®, RITUXIMAB®, PERJETA® and TARCEVA®. Prior to this, Pam was Research Director for the National Cancer Institute-Navy Breast Care Center that she co-founded and led until leaving the NCI. Pam received her bachelor’s degree in biology from California State University and her Medical Degree from Stritch School of Medicine, Loyola University Chicago. She trained in internal medicine at Cedars-Sinai Medical Center in Los Angeles and medical oncology at the National Cancer Institute in Bethesda, Maryland where she served as Chief Fellow.   

Darrell has served as an Advisor to Kenjockety since August, 2019 and brings nearly 30 years of experience as Chief Science Officer, Head of R&D, Senior Director and Director level positions in drug development spanning multiple clinical indications including oncology, CNS, inflammation (RA/OA), cardiovascular, pain management, metabolic disease, rare complement disorders and supportive care. Specific areas of experience and expertise include IND/NDA enabling toxicology, DMPK, clinical protocol and study report writing, PK data analysis and modeling, pharmacology, regulatory support and product strategy planning. Darrell is currently Vice President, Integrated Drug Development at Certara. He was President and Founder of a drug development consulting firm, DDC, LLC and acting VP of Development for Aquilus Pharmaceuticals and CSO of  Recardio Inc. Previously Darrell was the Sr. Director of Development at Gloucester Pharmaceuticals culminating in the successful Global registration of ISTODAX® prior to being acquired by Celgene in 2010. He led drug development at Alantos  Pharmaceuticals and on the M&A team that lead to an acquisition by Amgen in 2007. Prior to Alantos, Darrell was Sr. Director, Preclinical Development at Millennium Pharmaceuticals supporting development and commercialization of VELCADE™. Darrell was a distinguished member of the U.S. Army’s Medical Corp assigned to the US FDA in the Div. of Clinical Pharmacology at the USUHS in Bethesda. He has a BS in analytical chemistry and completed his graduate studies in Clinical Pharmacology at the Uniformed Services University of the Health Sciences (F. Edward Hebert School of Medicine), Bethesda, MD.  

Leonard has served as an Advisor to Kenjockety since April, 2019 and brings more than 30 years of experience in the biotechnology industry, primarily in protein/antibody engineering. Leonard is currently an independent consultant for numerous pharmaceutical and biotechnology companies and for several legal firms. Previously, while at Genentech he was responsible for the protein engineering that led to marketed therapeutic monoclonal antibodies HERCEPTIN®, RAPTIVA, XOLAIR®, AVASTIN®, LUCENTIS®, PERJETA®, OCREVUS®, and therapeutic protein TNKase®. Prior experience at Merck, Schering-Plough and DNAX included being responsible for protein and antibody engineering of therapeutic antibodies, including ILUMYA™. Leonard has been published extensively in peer-reviewed journals, an inventor on 175 issued U.S. patents, and an editorial board member for Journal of Biological Chemistry, PROTEINS, and MABS. Leonard earned his Ph.D. from Texas A&M University and holds a B.S. in chemistry and a B.S. in biology from the University of Arizona.

Qianting has been working with Kenjockety since July 2018. Qianting has over 15 years of experience in antibody discovery, antibody engineering, and protein engineering, and she has extensive experience in both structure-based protein and antibody engineering, as well as evolutionary technology-based engineering, such as phage display and mammalian display. Qianting was a team leader for therapeutic antibody discovery and antibody engineering for oncology and infectious diseases at Novartis AG. Qianting earned her Ph.D. degree in biochemistry from the University of Utah and completed her postdoc training at Genentech Inc. in the lab of Dr. Paul Carter.